Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer

Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer

Abstract Circulating IL-6, an activator of JAK/STAT signaling, is associated with poor prognosis and aromatase inhibitor (AI) resistance in hormone-receptor positive (HR+) breast cancer. Here we report the results of a phase 2 single-arm Simon 2-stage trial combining Ruxolitinib, an oral selective i...

Full description

Bibliographic Details
Main Authors: Igor Makhlin, Nicholas P. McAndrew, E. Paul Wileyto, Amy S. Clark, Robin Holmes, Lisa N. Bottalico, Clementina Mesaros, Ian A. Blair, Grace R. Jeschke, Kevin R. Fox, Susan M. Domchek, Jennifer M. Matro, Angela R. Bradbury, Michael D. Feldman, Elizabeth O. Hexner, Jacqueline F. Bromberg, Angela DeMichele
Format: Article
Language:English
Published: Nature Portfolio 2022-11-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-022-00487-x

Internet

https://doi.org/10.1038/s41523-022-00487-x

Similar Items